title: Bevacizumab versus ranibizumab: why are we not playing the joker?
authors.forename: Roberto
authors.initials: R
authors.lastname: Banfi
authors.forename: Francesco
authors.initials: F
authors.lastname: Attanasio
authors.forename: Nadia
authors.initials: N
authors.lastname: Palazzi
authors.forename: Silvia
authors.initials: S
authors.lastname: Colombini
authors.forename: Tiziana
authors.initials: T
authors.lastname: Falai
authors.forename: Michele
authors.initials: M
authors.lastname: Cecchi
authors.forename: Gianni
authors.initials: G
authors.lastname: Virgili
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D017277:Drug Approval; D016527:Drug Costs; D015195:Drug Design; D006801:Humans; D007558:Italy; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D056687:Off-Label Use; D000069579:Ranibizumab
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab